Cocktail treatment by GnRH-antagonist, letrozole, and mifepristone for the prevention of ovarian hyperstimulation syndrome: a prospective randomized trial

References

• Practice committee of the American society for reproductive medicine. Electronic address aao, practice committee of the American society for reproductive M: prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril. 2016;106(7):1–9.
   Web of Science ®Google Scholar
• Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update. 2003;9(1):77–96. doi: 10.1093/humupd/dmg005.
   PubMed Web of Science ®Google Scholar
• Braat DD, Schutte JM, Bernardus RE, et al. Maternal death related to IVF in The Netherlands 1984-2008. Hum Reprod. 2010;25(7):1782–1786. doi: 10.1093/humrep/deq080.
   PubMed Web of Science ®Google Scholar
• Cluroe AD, Synek BJ. A fatal case of ovarian hyperstimulation syndrome with cerebral infarction. Pathology. 1995;27(4):344–346. doi: 10.1080/00313029500169273.
   PubMed Web of Science ®Google Scholar
• Wang YQ, Luo J, Xu WM, et al. Can steroidal ovarian suppression during the luteal phase after oocyte retrieval reduce the risk of severe OHSS? J Ovarian Res. 2015;8(1):63. doi: 10.1186/s13048-015-0190-y.
   PubMedGoogle Scholar
• Mai Q, Hu X, Yang G, et al. Effect of letrozole on moderate and severe early-onset ovarian hyperstimulation syndrome in high-risk women: a prospective randomized trial. Am J Obstet Gynecol. 2017;216(1):42 e41–42 e10.
   Web of Science ®Google Scholar
• Toftager M, Bogstad J, Bryndorf T, et al. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles. Hum Reprod. 2016;31(6):1253–1264. doi: 10.1093/humrep/dew051.
   PubMed Web of Science ®Google Scholar
• Humaidan P, Nelson SM, Devroey P, et al. Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials. Hum Reprod. 2016;31(9):1997–2004. doi: 10.1093/humrep/dew149.
   PubMed Web of Science ®Google Scholar
• Casper RF, Yen SS. Induction of luteolysis in the human with a long-acting analog of luteinizing hormone-releasing factor. Science. 1979;205(4404):408–410. doi: 10.1126/science.377491.
   PubMed Web of Science ®Google Scholar
• Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril. 2004;81(1):1–5. doi: 10.1016/j.fertnstert.2003.05.032.
   PubMed Web of Science ®Google Scholar
• McCracken JA, Custer EE, Lamsa JC. Luteolysis: a neuroendocrine-mediated event. Physiol Rev. 1999;79(2):263–323. doi: 10.1152/physrev.1999.79.2.263.
   PubMed Web of Science ®Google Scholar
• Ferrero H, Garcia-Pascual CM, Gaytan M, et al. Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in an ovarian hyperstimulation syndrome (OHSS) animal model: implications for treatment of OHSS with dopamine receptor 2 agonists. Fertil Steril. 2014;102(5):1468–1476 e1461. doi: 10.1016/j.fertnstert.2014.07.1240.
   PubMed Web of Science ®Google Scholar
• Elmahdy M, Abdelsalam EA, Maghraby HA. Combining several interventions to reduce the incidence of OHSS: a prospective cohort study. Eur J Obstet Gynecol Reprod Biol. 2017;212:110–114. doi: 10.1016/j.ejogrb.2017.03.016.
   PubMed Web of Science ®Google Scholar
• Golan A, Weissman A. Symposium: update on prediction and management of OHSS. A modern classification of OHSS. Reprod Biomed Online. 2009;19(1):28–32. doi: 10.1016/s1472-6483(10)60042-9.
   PubMed Web of Science ®Google Scholar
• Ajonuma LC. Is vascular endothelial growth factor (VEGF) the main mediator in ovarian hyperstimulation syndrome (OHSS)? Med Hypotheses. 2008;70(6):1174–1178. doi: 10.1016/j.mehy.2007.11.004.
   PubMed Web of Science ®Google Scholar
• Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. Reprod Biol Endocrinol. 2012;10(1):32. doi: 10.1186/1477-7827-10-32.
   PubMedGoogle Scholar
• Lainas GT, Kolibianakis EM, Sfontouris IA, et al. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS. Hum Reprod. 2013;28(7):1929–1942. doi: 10.1093/humrep/det114.
   PubMed Web of Science ®Google Scholar
• Lainas GT, Kolibianakis EM, Sfontouris IA, et al. Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study. Reprod Biol Endocrinol. 2012;10(1):69. doi: 10.1186/1477-7827-10-69.
   PubMedGoogle Scholar
• He Q, Liang L, Zhang C, et al. Effects of different doses of letrozole on the incidence of early-onset ovarian hyperstimulation syndrome after oocyte retrieval. Syst Biol Reprod Med. 2014;60(6):355–360. doi: 10.3109/19396368.2014.957879.
   PubMed Web of Science ®Google Scholar
• Goddard LM, Murphy TJ, Org T, et al. Progesterone receptor in the vascular endothelium triggers physiological uterine permeability preimplantation. Cell. 2014;156(3):549–562. doi: 10.1016/j.cell.2013.12.025.
   PubMed Web of Science ®Google Scholar
• Ohba T, Ujioka T, Ishikawa K, et al. Ovarian hyperstimulation syndrome-model rats; the manifestation and clinical implication. Mol Cell Endocrinol. 2003;202(1-2):47–52. doi: 10.1016/s0303-7207(03)00061-3.
   PubMed Web of Science ®Google Scholar
• Ishikawa K, Ohba T, Tanaka N, et al. Organ-specific production control of vascular endothelial growth factor in ovarian hyperstimulation syndrome-model rats. Endocr J. 2003;50(5):515–525. doi: 10.1507/endocrj.50.515.
   PubMed Web of Science ®Google Scholar
• Luo J, Qi Q, Chen Y, et al. Effect of GnRH-antagonist, mifepristone and letrozole on preventing ovarian hyperstimulation syndrome in rat model. Reprod Biomed Online. 2021;42(2):291–300. doi: 10.1016/j.rbmo.2020.10.006.
   PubMed Web of Science ®Google Scholar
• Pundir J, Sunkara SK, El-Toukhy T, et al. Meta-analysis of GnRH antagonist protocols: do they reduce the risk of OHSS in PCOS? Reprod Biomed Online. 2012;24(1):6–22. doi: 10.1016/j.rbmo.2011.09.017.
   PubMed Web of Science ®Google Scholar
• Lambalk CB, Banga FR, Huirne JA, et al. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update. 2017;23(5):560–579. doi: 10.1093/humupd/dmx017.
   PubMed Web of Science ®Google Scholar
• Sridev S, Barathan S. Case report on spontaneous ovarian hyperstimulation syndrome following natural conception associated with primary hypothyroidism. J Hum Reprod Sci. 2013;6(2):158–161. doi: 10.4103/0974-1208.117164.
   PubMedGoogle Scholar
• Wang TH, Horng SG, Chang CL, et al. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. J Clin Endocrinol Metab. 2002;87(7):3300–3308. doi: 10.1210/jcem.87.7.8651.
   PubMed Web of Science ®Google Scholar
• Alvarez C, Marti-Bonmati L, Novella-Maestre E, et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab. 2007;92(8):2931–2937. doi: 10.1210/jc.2007-0409.
   PubMed Web of Science ®Google Scholar
• Aberdeen GW, Wiegand SJ, Bonagura TW, Jr., et al. Vascular endothelial growth factor mediates the estrogen-induced breakdown of tight junctions between and increase in proliferation of microvessel endothelial cells in the baboon endometrium. Endocrinology. 2008;149(12):6076–6083. doi: 10.1210/en.2008-0521.
   PubMed Web of Science ®Google Scholar
• Vrtacnik-Bokal E, Virant Klun I, Verdenik I. Follicular oestradiol and VEGF after GnRH antagonists or GnRH agonists in women with PCOS. Reprod Biomed Online. 2009;18(1):21–28. doi: 10.1016/s1472-6483(10)60420-8.
   PubMed Web of Science ®Google Scholar
• Cerrillo M, Rodriguez S, Mayoral M, et al. Differential regulation of VEGF after final oocyte maturation with GnRH agonist versus hCG: a rationale for OHSS reduction. Fertil Steril. 2009;91(4):1526–1528. doi: 10.1016/j.fertnstert.2008.08.118.
   PubMed Web of Science ®Google Scholar
• Group ECPW, Vlaisavljevic V, Apter S, et al. The maribor consensus: report of an expert meeting on the development of performance indicators for clinical practice in ART. Hum Reprod Open. 2021;2021(3):hoab022.
   PubMedGoogle Scholar